Three companies have reached a strategic partnership on the type 2 diabetes drug Acapo sugar

Recently, UnitedCom Biotech Group Co., Ltd. ("Union Health Group") announced that its wholly-owned subsidiary Beijing Bokang Health Genetic Technology Co., Ltd. has reached strategic cooperation with ("Beijing BokangJian"), China Pharmaceutical Group Wichida Pharmaceutical Co., Ltd. ("National Pharmaceutical Wichida") and Suzhou Yingli Pharmaceutical Technology Co., Ltd. ("Suzhou Yingli") on the Group's type 2 diabetes drug Akabo Sugar (commodity name: Boshutai). The partnership aims to fully realize the clinical, social and market value of the product.According to the agreement, Suzhou Camp is responsible for the early research and development of Akapo sugar API, the national drug Wichida is responsible for the completion of the industrial development, production and supply of Akapo sugar API, and Beijing Bokangjian obtained at least 10 years of stable supply of Akapo sugar API, for the commercialization of products and strive to be selected as Akapo sugar national volume procurement.Acapo sugar was included in the second batch of belt purchases, which opened in January this year, with the original manufacturer Bayer and Green leaf Pharmaceuticals winning the bid. According to GBI SOURCE data, Beijing Bokang health in October 2019 submitted two applications for the listing of akapo sugar generic drugs, and was accepted by the National Drug Administration (NMPA). Wichida, a wholly owned subsidiary of Shanghai Hyundai Pharmaceutical Co., Ltd., will take advantage of the policy dividend of the Drug Listing License Holder (MAH) system, which allows holders to entrust entrusted manufacturers with the production of medicines.Liang Guolong, chairman of UC Group, explained the reasons behind the deal: "The partnership with Wichida is critical to the commercialization of the company's Acapo sugar. In China's new market competition environment, cost leadership strategy is the key to the success of all generic drugs to win the market. This cooperation is conducive to all parties to play their respective advantages, through the industry chain upstream and downstream close cooperation, we are able to compete in only four companies worth 8.4 billion yuan in the market. To put it simply, a 10 per cent market share would be Rmb840m in sales, four times the group's 2019 sales. "Unlike in the past, the new market environment means that we do not need to invest in the market and then get slow-growing revenues; "(Sina Medical News)